Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Or we're forming the right shoulder on the hourly. Possibility?
NNSR - A breakout above .081 and we gooooooooooo.
EMFP - A bb stock poised to breakout above $2. Does the F/A support a higher price? and are there any hidden traps? Please.
Looks like an upgrade to Sharpcharts 2 is needed for that chart.
I did pick up some ISRG June 105 Puts, though.
No :(((( Greed is a terrible thing. Actually, I bought this as a longer term play (Aug Calls), so I don't feel too badly.
MRVL moving up, early.
Now if the SP will only reflect that future.
STXN - Due for a bounce? Chart at bottom.
Stratex Swings to Profit in 4Q
Thursday May 18, 5:31 pm ET
Stratex Networks Swings to 4Q Profit, Boosted by Strong Rise in Sales
SAN JOSE, Calif. (AP) -- Stratex Networks Inc., which makes digital microwave radios for communications systems, swung to a profit in its fiscal fourth quarter, boosted by a strong increase in sales.
Fourth-quarter Net income increased to $3.3 million, or 3 cents per share, compared to a loss of $13.3 million, or 14 cents per share, during the year-ago period. Excluding charges from stock-based compensation, Stratex Networks posted net income of $3.4 million, or 3 cents per share, in the fourth quarter.
Revenue increased 56 percent to $64 million, compared to $41.1 million in the year-ago period.
Analysts predicted earnings of 2 cents per share on revenue of $62.2 million, according to a Thomson Financial poll.
For the fiscal year, the company posted a loss of $2.3 million, or 2 cents per share, compared with a loss of $45.9 million, or 51 cents per share, the year before.
Revenue for the year increased 28 percent to $230.9 million, compared to $180.3 million a year ago.
Excluding stock-based compensation, net loss for 2006 was $800,000, or a penny per share.
Looking ahead, the company expects first-quarter revenue to range between $62 million and $66 million, with earnings per share in the range of 2 cents per share to 4 cents per share. Wall Street is looking for earnings of 3 cents per share on revenue of $62 million.
Separately, the company said it appointed Thomas H. Waechter as president and chief executive. Waechter, who has been an independent director of Stratex since December, succeeds Chuck Kissner, who will remain as executive chairman.
The company also appointed John Brandt, the company's vice president of global operations, as vice president of business development.
Stratex stock fell 24 cents, or 4.6 percent, to close at $5 on the Nasdaq, but regained 5 cents in aftermarket activity. In a 52-week period, shares of Stratex have traded between $1.45 and $6.58.
MZT - News/PR
Studies Presented at American Urological Association Expand the Role of the NMP22(R) BladderChek(R) Test
Business Wire - May 24, 2006 09:00
NEWTON, Mass., May 24, 2006 (BUSINESS WIRE) -- Matritech
Improves Bladder Cancer Detection to 99% - Aiding the Earlier Detection of Cancer
Reported to Indicate Likelihood of Life Threatening Bladder Malignancy
Recommended for use in Screening High Risk Populations for Bladder Cancer to Save Lives and Reduce Expense
4 Times More Effective than the Conventional Laboratory Urine Test in Detecting Recurrent Bladder Cancer
Matritech (Amex: MZT) reported today that independent clinical investigators recommended the NMP22(R) BladderChek(R) Test be included in standard practice for diagnosing and monitoring bladder cancer. The test was featured and included in a number of presentations, which highlighted the clinical utility of the point-of-care urine diagnostic test in bladder cancer diagnosis, monitoring and screening, at this year's 101st Annual Meeting of the American Urological Association (AUA) in Atlanta.
"The presentations, and particularly the support from these highly respected clinicians, have delivered a compelling message about the benefits the NMP22 BladderChek Test can provide in standard practice from diagnosing and monitoring bladder cancer to its potential for saving lives and expense in screening people who are at risk for the cancer," said Stephen D. Chubb, Chairman and CEO of Matritech.
Highlights from the NMP22 BladderChek Test presentations included:
-- when used in combination with cystoscopy significantly improved the detection of recurring bladder cancer to 99%;
-- was positive for 8 of 9 cancers not seen by cystoscopy, including seven tumors that were aggressive or advanced;
-- detected four times as many cancers as the laboratory based urine cytology test; is the only urine test shown to indicate whether a bladder malignancy is likely to be dangerous;
-- has the potential to save lives and reduce expense in screening high risk populations for bladder cancer - all other cancer screening programs save lives but increase expense.
The NMP22 BladderChek Test was featured in two presentations in the podium session: Screening and Diagnosing Bladder Cancer; a discussed poster presentation; a session reviewing the latest information on bladder cancer screening; and a continuing medical education symposium.
Bladder cancer diagnosis and monitoring data were presented by three U.S. urologists, regarded as authorities in bladder cancer research and clinical care:
-- H. Barton Grossman, M.D., Deputy Chairman, Department of Urology, M.D. Anderson Cancer Center, Houston, TX
-- Mark Soloway, M.D., Chairman of the Department of Urology at the University of Miami Leonard M. Miller School of Medicine
-- Barry Stein, M.D., Surgeon-in-Chief of Urology, Rhode Island Hospital and Professor of Urology, Brown Medical School
They are also among the authors of the multicenter studies for bladder cancer diagnosis and surveillance published in the Journal of the American Medical Association (JAMA) in January 2006 and February 2005.
New information about the cost effectiveness and life years saved by including bladder cancer screening into mainstream medical care was presented by:
-- Yair Lotan, M.D., Assistant Professor, Department of Urology, University of Texas Southwestern Medical Center
Dr. Lotan's study demonstrated that screening for bladder cancer can save money as well as lives, by finding more cancers before they become muscle invasive. Not only is prognosis much better in patients with earlier stage disease, but the expense of treatment is substantially less. If testing is focused on patients at high risk and conducted with the low cost NMP22(R) BladderChek(R) Test the money saved in treatment expense is greater than the cost of screening.
The ability of a screening program to reduce bladder cancer mortality was emphasized in another podium presentation by Edward Messing, M. D., Chairman of the Urology Department, University of Rochester Medical Center, also an author of the two published JAMA reports on the NMP22 BladderChek Test. His long term follow up of patients screened for bladder cancer demonstrated that overall mortality was significantly lower in bladder cancer patients diagnosed by early screening (43%) vs. those whose disease was not detected by early screening (74 %). Screening allowed more cancers to be found early, thereby decreasing the number of bladder-cancer mortalities over time in this group. This presentation was included in a plenary session.
The NMP22 BladderChek Test is not meant to replace cystoscopy (a visual examination of the inside of the bladder with a lighted scope), an examination often considered the "gold standard" for diagnosing bladder cancer. Every NMP22 BladderChek Test result, however, provides clinically useful information when used in combination with cystoscopy. It is also the only urine test approved by the FDA (by prescription) for home use as an aid in diagnosing bladder cancer.
Dr. Soloway commented, "Using the NMP22 BladderChek Test with cystoscopy adds useful information to enhance our ability to detect and treat a cancer. Cystoscopy is very good, but not perfect--that's why physicians use adjunctive tests."
Dr. Grossman also said, "The combination of the NMP22 test with cystoscopy detected significantly more cancers than cystoscopy alone. Adding the NMP22 test improved detection. Moreover, it's easy to use in an office setting, provides an answer in half an hour, and is inexpensive."
Other discussions of the NMP22(R) BladderChek(R) Test included an overview by Dr. Grossman in a continuing medical education program (CME), Bladder Cancer: Practical Considerations in the Use of Markers, A Case-based Symposium. In his introduction to this course, which was intended to keep physicians up to date on the uses of tumor markers, he pointed out that the NMP22 BladderChek Test was proven to identify cancers missed by cystoscopy in two large clinical trials, citing the publications in JAMA. He also emphasized that when using any diagnostic test it is important to understand its performance characteristics. As an example, he compared the NMP22 BladderChek Test to a common laboratory analysis, urine cytology. Dr. Grossman drew attention to the significantly better negative predictive value (NPV), or reliability of a negative test result, of the point-of-care test, which has fewer missed cancers (false negatives).
About the NMP22(R) BladderChek(R) Test
The NMP22(R) BladderChek(R) Test was developed and commercialized by Matritech, a leading developer and marketer of protein-based diagnostic products for the early detection of cancer. The NMP22 BladderChek Test detects elevated levels of the NMP22 protein marker in a single urine sample. Most healthy individuals have very small amounts of the NMP22 protein marker in their urine, but bladder cancer patients commonly have elevated NMP22 protein marker levels, even at early stages of the disease.
The NMP22 BladderChek Test, a painless and noninvasive assay, is the only in-office test approved by the FDA for both the diagnosis and monitoring of bladder cancer. It is used in a physician's office, requires only four drops of urine and results are available in 30 minutes - during the patient visit, allowing a rapid, and accurate way to aid in the detection of bladder cancer. The NMP22 BladderChek Test is reimbursed by Medicare and many other medical insurers and has an average cost of less than $30. It also has been shown to detect over three times as many cancers as the commonly used laboratory based urine cytology test.
Two studies published in the Journal of the American Medical Association (JAMA) in February 2005 and January 2006 reported on clinical data showing the NMP22 BladderChek Test, used in combination with cystoscopy (a visual examination of the interior of the bladder using a scope inserted through the urethra), in the diagnosing and monitoring of bladder cancer detected up to 99% of bladder malignancies. The NMP22 BladderChek Test also detected cancers that were missed during an initial cystoscopic examination, most of which were high grade. In other clinical study analyses the NMP22 BladderChek Test was shown to detect 100% of the aggressive tumors, one of which was muscle invasive, in women with symptoms or risk factors for bladder cancer. The test was also reported to detect all of the cancers that occurred in the upper urinary tract of patients with risk factors or symptoms of bladder cancer. Cystoscopy did not identify these tumors because they were outside the viewing area of the instrument.
About Matritech
Matritech is using its patented proteomics technology to develop diagnostics for the detection of a variety of cancers. The Company's first two products, the NMP22(R) Test Kit and NMP22(R) BladderChek(R) Test, have been FDA approved for the monitoring and diagnosis of bladder cancer. The NMP22 BladderChek Test is based on Matritech's proprietary nuclear matrix protein (NMP) technology, which correlates levels of NMPs in body fluids to the presence of cancer. Beginning with a patent portfolio licensed exclusively from the Massachusetts Institute of Technology (MIT), Matritech's patent portfolio has grown to more than 15 other U.S. patents. In addition to the NMP22 protein marker utilized in the NMP22 Test Kit and NMP22 BladderChek Test, the Company has discovered other proteins associated with cervical, breast, prostate, and colon cancer. The Company's goal is to utilize these protein markers to develop, through its own research staff and through strategic alliances, clinical applications to detect cancer. More information about Matritech is available at www.matritech.com.
Mornin' icon, Looks like a pretty one here in the DC area.
PPHM - News
Peregrine Pharmaceuticals' Bavituximab Shows Potential Activity Against Avian Flu in Initial Testing
PR Newswire - May 24, 2006 07:01
- Initial Data Presented at ASM Meeting Show Complete Inhibition of Viral Replication in H5N1 In Vivo Model - - Supported by In Vitro Data Confirming Bavituximab Binds to H5N1 Viral Particles -
TUSTIN, Calif. and ORLANDO, Fla., May 24, 2006 /PRNewswire-FirstCall via COMTEX/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a biopharmaceutical company with a portfolio of innovative, clinical stage product candidates for the treatment of hepatitis C virus (HCV) infection and cancer, today announced that its lead anti-viral compound bavituximab (formerly Tarvacin) completely inhibited replication of a laboratory strain of the H5N1 virus, commonly known as avian flu, in fertilized chicken eggs, an in vivo model for influenza anti- viral activity. These preliminary findings will be reported today at the 106th general meeting of The American Society for Microbiology (ASM) in Orlando, Florida by Dr. Philip Thorpe, a member of the Peregrine Scientific Resource Board and professor of pharmacology at the University of Texas Southwestern Medical Center at Dallas. Bavituximab, a monoclonal antibody with unique anti-viral and anti-cancer properties, has already demonstrated good tolerability in a Phase l trial in patients with HCV infection.
"This first set of results showing that bavituximab appears to have inhibited H5N1 viral replication in the fertilized egg model and the supportive data confirming that bavituximab binds to H5N1 viral particles are encouraging," said Dr. Thorpe. "These early data support the view that bavituximab may be active against H5N1 and other common strains of influenza."
The H5N1 studies reported by Dr. Thorpe were conducted at a number of independent research laboratories. Peregrine has also been collaborating with other researchers to evaluate the potential of bavituximab delivered by different routes of administration to treat infections caused by influenza A, the viral family that includes the H5N1 strain. Peregrine has ongoing studies to evaluate various delivery methods and treatment regimens to treat influenza in a number of in vivo models, including well-established mouse and ferret models. These studies include assessments of bavituximab delivered by nasal inhalation, a form of delivery expected to be more effective than systemic delivery alone for respiratory viruses that lodge deep in the lungs.
"These early experimental data suggesting that bavituximab may have activity against the avian flu, along with preliminary data recently generated showing signs of activity in a ferret model of influenza A infection, give us momentum and direction as we pursue a variety of preclinical initiatives to assess the anti-viral potential of bavituximab," said Steven W. King, president and CEO of Peregrine. "With a repeat dose safety study in HCV patients expected to begin next month, we should be well-positioned to initiate clinical trials for bavituximab in additional indications once we have sufficient preclinical data in hand."
Bavituximab is an antibody that attaches to specific cellular components called phospholipids found on the surface of virus particles, including influenza and certain other virus strains, as well as on the outer surface of human host cells only when they are infected with these viruses. Bavituximab helps stimulate the body's natural immune defenses to destroy both the virus particles and the infected cells, without affecting healthy cells. Bavituximab is in Phase 1 clinical trials for hepatitis C virus infections and for solid tumor cancers. A Phase 1b repeat dose study in HCV patients is expected to start in June.
Dr. Thorpe's ASM presentation, Broad-Spectrum Anti-Virals, is scheduled for May 24th at 10:00am in Room 208A as part of a symposium on Bioterrorism: Challenges and Opportunities.
PPHM - News
Peregrine Pharmaceuticals' Bavituximab Shows Potential Activity Against Avian Flu in Initial Testing
PR Newswire - May 24, 2006 07:01
- Initial Data Presented at ASM Meeting Show Complete Inhibition of Viral Replication in H5N1 In Vivo Model - - Supported by In Vitro Data Confirming Bavituximab Binds to H5N1 Viral Particles -
TUSTIN, Calif. and ORLANDO, Fla., May 24, 2006 /PRNewswire-FirstCall via COMTEX/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a biopharmaceutical company with a portfolio of innovative, clinical stage product candidates for the treatment of hepatitis C virus (HCV) infection and cancer, today announced that its lead anti-viral compound bavituximab (formerly Tarvacin) completely inhibited replication of a laboratory strain of the H5N1 virus, commonly known as avian flu, in fertilized chicken eggs, an in vivo model for influenza anti- viral activity. These preliminary findings will be reported today at the 106th general meeting of The American Society for Microbiology (ASM) in Orlando, Florida by Dr. Philip Thorpe, a member of the Peregrine Scientific Resource Board and professor of pharmacology at the University of Texas Southwestern Medical Center at Dallas. Bavituximab, a monoclonal antibody with unique anti-viral and anti-cancer properties, has already demonstrated good tolerability in a Phase l trial in patients with HCV infection.
"This first set of results showing that bavituximab appears to have inhibited H5N1 viral replication in the fertilized egg model and the supportive data confirming that bavituximab binds to H5N1 viral particles are encouraging," said Dr. Thorpe. "These early data support the view that bavituximab may be active against H5N1 and other common strains of influenza."
The H5N1 studies reported by Dr. Thorpe were conducted at a number of independent research laboratories. Peregrine has also been collaborating with other researchers to evaluate the potential of bavituximab delivered by different routes of administration to treat infections caused by influenza A, the viral family that includes the H5N1 strain. Peregrine has ongoing studies to evaluate various delivery methods and treatment regimens to treat influenza in a number of in vivo models, including well-established mouse and ferret models. These studies include assessments of bavituximab delivered by nasal inhalation, a form of delivery expected to be more effective than systemic delivery alone for respiratory viruses that lodge deep in the lungs.
"These early experimental data suggesting that bavituximab may have activity against the avian flu, along with preliminary data recently generated showing signs of activity in a ferret model of influenza A infection, give us momentum and direction as we pursue a variety of preclinical initiatives to assess the anti-viral potential of bavituximab," said Steven W. King, president and CEO of Peregrine. "With a repeat dose safety study in HCV patients expected to begin next month, we should be well-positioned to initiate clinical trials for bavituximab in additional indications once we have sufficient preclinical data in hand."
Bavituximab is an antibody that attaches to specific cellular components called phospholipids found on the surface of virus particles, including influenza and certain other virus strains, as well as on the outer surface of human host cells only when they are infected with these viruses. Bavituximab helps stimulate the body's natural immune defenses to destroy both the virus particles and the infected cells, without affecting healthy cells. Bavituximab is in Phase 1 clinical trials for hepatitis C virus infections and for solid tumor cancers. A Phase 1b repeat dose study in HCV patients is expected to start in June.
Dr. Thorpe's ASM presentation, Broad-Spectrum Anti-Virals, is scheduled for May 24th at 10:00am in Room 208A as part of a symposium on Bioterrorism: Challenges and Opportunities.
PPHM - News
Peregrine Pharmaceuticals' Bavituximab Shows Potential Activity Against Avian Flu in Initial Testing
PR Newswire - May 24, 2006 07:01
- Initial Data Presented at ASM Meeting Show Complete Inhibition of Viral Replication in H5N1 In Vivo Model - - Supported by In Vitro Data Confirming Bavituximab Binds to H5N1 Viral Particles -
TUSTIN, Calif. and ORLANDO, Fla., May 24, 2006 /PRNewswire-FirstCall via COMTEX/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a biopharmaceutical company with a portfolio of innovative, clinical stage product candidates for the treatment of hepatitis C virus (HCV) infection and cancer, today announced that its lead anti-viral compound bavituximab (formerly Tarvacin) completely inhibited replication of a laboratory strain of the H5N1 virus, commonly known as avian flu, in fertilized chicken eggs, an in vivo model for influenza anti- viral activity. These preliminary findings will be reported today at the 106th general meeting of The American Society for Microbiology (ASM) in Orlando, Florida by Dr. Philip Thorpe, a member of the Peregrine Scientific Resource Board and professor of pharmacology at the University of Texas Southwestern Medical Center at Dallas. Bavituximab, a monoclonal antibody with unique anti-viral and anti-cancer properties, has already demonstrated good tolerability in a Phase l trial in patients with HCV infection.
"This first set of results showing that bavituximab appears to have inhibited H5N1 viral replication in the fertilized egg model and the supportive data confirming that bavituximab binds to H5N1 viral particles are encouraging," said Dr. Thorpe. "These early data support the view that bavituximab may be active against H5N1 and other common strains of influenza."
The H5N1 studies reported by Dr. Thorpe were conducted at a number of independent research laboratories. Peregrine has also been collaborating with other researchers to evaluate the potential of bavituximab delivered by different routes of administration to treat infections caused by influenza A, the viral family that includes the H5N1 strain. Peregrine has ongoing studies to evaluate various delivery methods and treatment regimens to treat influenza in a number of in vivo models, including well-established mouse and ferret models. These studies include assessments of bavituximab delivered by nasal inhalation, a form of delivery expected to be more effective than systemic delivery alone for respiratory viruses that lodge deep in the lungs.
"These early experimental data suggesting that bavituximab may have activity against the avian flu, along with preliminary data recently generated showing signs of activity in a ferret model of influenza A infection, give us momentum and direction as we pursue a variety of preclinical initiatives to assess the anti-viral potential of bavituximab," said Steven W. King, president and CEO of Peregrine. "With a repeat dose safety study in HCV patients expected to begin next month, we should be well-positioned to initiate clinical trials for bavituximab in additional indications once we have sufficient preclinical data in hand."
Bavituximab is an antibody that attaches to specific cellular components called phospholipids found on the surface of virus particles, including influenza and certain other virus strains, as well as on the outer surface of human host cells only when they are infected with these viruses. Bavituximab helps stimulate the body's natural immune defenses to destroy both the virus particles and the infected cells, without affecting healthy cells. Bavituximab is in Phase 1 clinical trials for hepatitis C virus infections and for solid tumor cancers. A Phase 1b repeat dose study in HCV patients is expected to start in June.
Dr. Thorpe's ASM presentation, Broad-Spectrum Anti-Virals, is scheduled for May 24th at 10:00am in Room 208A as part of a symposium on Bioterrorism: Challenges and Opportunities.
ISRG - Looking very weak. I doubt the blue trend will hold. Will this pull a TASR?
I'm happy with it, but I grabbed it before Susan could and she had to go find another. Maybe I should member mark her, ya think?
You can thank me later. LOL
Had superb earnings for Q1 and ripped it. Pulled back on Friday, Monday and this morning to retest support and turned back up. Let's see how committed the buyers are.
You didn't even mention the almost perfect H&S that formed from Dec. - Apr.
MRVL Aug 55 Calls
Can I go back to being sweet, loveable Snap, now? LOL
OK, I'll play the bear. What do you make of the candle today? Take a look at the high closing candle for the year back in late April. Except for the shadow on today's candle, they sure do look similar.
BA getting back in the swing. Picked the wrong trendline earlier, but how was I to know the whole market would collapse.
You already won at least once on that pick. Share the wealth, eh? LOL
Gapper = OTD. Thought I'd beat the crowd. :)
FMLY - Back inside the bollies and turning back up.
OTD - Bottoming?
"Chavez could just take it over whenever he wants to!"
Probably will wait for KRY to get it developed and into production, then make his move. Why should he spend the money for the up front development costs?
Is IHub having problems this morning or is it my connection?
KOOL - Looks ripe for a run.
RBAK - Anybody have any experience with trendlines on the RSI? Could be the start of a new leg up, or a topping out if an RSI trend break does not occur.
PDCO - Turning back up? Nice gap to fill.
KOMG - Trend break?
ENR - Double bottom?
And Cramer likes it...
Whatever that's worth. It is also a South America play which, in my eyes, makes it a little higher risk.
Are they into that as well? The tech where the surface of electrical wires carry the data signal, while the body provides the power, or something like that? I always liked the idea. No extra connections like cable or DSL. What was the company that was supposed to get it off the ground in NY, but never could seem the get it going?
Can you imagine the market in high density housing retrofits?
Golly, I don't quite know what to say about that last remark. Nothing that would be in keeping with proper decorum, so I will simply congratulate you on an excellent choice for your alias.
:)
Oh, yeah. Be sure to let us all know when CPTC looks ready to go. I will be reloading if it starts to consolidate at this level.
Very interesting analysis and one which I agree with. I find it interesting that you like CPTC. I have been following it and believe their time is near, now that the bankruptcy issues have been laid to rest. Played that last spike and am waiting for it to stabilize to take another position.
Thanks. Thought it was about time and it went at HOD at 3:59.
Will be watching MRVL very closely tomorrow. Awesome Earnings report.
http://biz.yahoo.com/prnews/060518/sfth075.html?.v=50
MRVL - I wonder what thwey will find wrong with this earnings report.
http://biz.yahoo.com/prnews/060518/sfth075.html?.v=50
Out ISRG June 120 Puts just before the bell @ 9.70 from 6.10.